首页> 美国卫生研究院文献>other >Comparative Effectiveness of Biosimilar Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study

【2h】

Comparative Effectiveness of Biosimilar Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study

机译：生物仿制药参考产品和其他促红细胞生成剂（ESA）在慢性肾脏疾病和癌症患者中仍具有专利的比较效力：一项基于意大利人群的研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundSince 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Italian market. Very limited post-marketing data exist on the comparative effectiveness of biosimilar and originator ESAs.

机译：背景技术自2007年以来，红细胞生成刺激剂（ESA）的生物仿制药开始在意大利市场上销售。关于生物仿制药和原研药ESA相对有效性的售后数据非常有限。

著录项

期刊名称 other
作者
Ylenia Ingrasciotta; Francesco Giorgianni; Ilaria Marcianò; Jenny Bolcato; Roberta Pirolo; Alessandro Chinellato; Valentina Ientile; Domenico Santoro; Armando A. Genazzani; Angela Alibrandi; Andrea Fontana; Achille P. Caputi; Gianluca Trifirò;
展开▼
作者单位

展开▼
年(卷),期 -1(11),5
年度 -1
页码 e0155805
总页数 16
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology [J] . Motola Domenico, Vaccheri Alberto, Roncadori Andrea, European journal of clinical pharmacology . 2018,第6期

机译：生物仿制剂和发起促进剂促红细胞刺激剂（ESAs）的比较风险/益处概况：来自肾脏的意大利观测研究的数据
2. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients [J] . Roberto Minutolo, Piergiorgio Bolasco, Paolo Chiodini, Clinical drug investigation . 2017,第10期

机译：切换到促红细胞生物刺激剂（ESA）生物仿制剂与ESA发起者维持的有效性：血液透析患者的匹配对照研究
3. How Much Are Biosimilars Used in Clinical Practice? A Retrospective Italian Population-Based Study of Erythropoiesis-Stimulating Agents in the Years 2009-2013 [J] . Ingrasciotta Ylenia, Giorgianni Francesco, Bolcato Jenny, BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2015,第4期

机译：在临床实践中使用了多少生物仿制药？一项基于意大利人群的回顾性研究，研究2009-2013年促红细胞生成因子
4. A Markov Model Study on the Hierarchical Prognosis and Risk Factors in Patients with Chronic Kidney Disease [C] . Liu Xun, Lv Linsheng, Ling Li, Computer Science and Electronics Engineering (ICCSEE), 2012 International Conference on . 2012

机译：慢性肾脏病患者分层预后及其危险因素的马尔可夫模型研究
5. Utilization patterns and economic impact of IV iron and erythropoiesis stimulating agents in chronic kidney disease patients: A multi-hospital study [D] . Joshi, Avani D. 2010

机译：慢性肾脏病患者静脉输注铁和促红细胞生成素刺激剂的使用模式和经济影响：一项多院研究
6. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy [O] . Francesco Trotta, Valeria Belleudi, Danilo Fusco, 2017

机译：促红细胞生成剂（生物仿制药与原始药物）在临床实践中的比较有效性和安全性：一项基于人群的意大利队列研究
7. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study [O] . Ingrasciotta Y. (Ylenia), Giorgianni F. (Francesco), Marcianò I. (Ilaria), 2016

机译：生物仿制药，参考产品和其他促红细胞生成剂（ESA）在慢性肾脏疾病和癌症患者中仍具有专利的比较效力：一项基于意大利人群的研究
8. Chronic Kidney Disease Stages 13: Screening, Monitoring, and Treatment. Executive Summary. Effective Health Care Program. Comparative Effectiveness Review Number 37. [R] . 2012

机译：慢性肾病阶段13：筛查，监测和治疗。执行摘要。有效的医疗保健计划。比较效力评估编号37。

Comparative Effectiveness of Biosimilar Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study

摘要

著录项

相似文献

相关主题

期刊订阅